Physician profile
Pedro Caro
NPI 1487618096
$1,800.79
in general payments reported to CMS, 2019-2025
16 companies · $609 in 2025
The $609 reported for 2025 was more than what 86% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2022: $88.62 · 2023: $292 · 2024: $604 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $421.09 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $298.05 | 2023-2025 | Rexulti |
| Eisai INC. | $249.74 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $202.80 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.22 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.20 | 2025 | Jardiance |
| Abbvie INC. | $80.76 | 2022-2023 | Vraylar |
| Lilly USA, LLC | $74.82 | 2019-2025 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $51.62 | 2019 | |
| Abbott Laboratories | $46.48 | 2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $45.41 | 2019 | |
| Novo Nordisk INC | $28.83 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $19.18 | 2019 | |
| Merck Sharp & Dohme LLC | $17.39 | 2019 | |
| Almatica Pharma LLC | $16.83 | 2024 | Loreev Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Caro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.